United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $859,716.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $238.81, for a total transaction of $859,716.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $31,045.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $233.85 on Friday. The firm’s 50 day moving average is $233.74 and its two-hundred day moving average is $228.80. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $261.54. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The company has a market cap of $11.00 billion, a P/E ratio of 11.79 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. During the same quarter last year, the firm posted $2.67 EPS. The business’s revenue for the quarter was up 25.1% compared to the same quarter last year. Analysts expect that United Therapeutics Co. will post 23.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on UTHR shares. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. The Goldman Sachs Group raised shares of United Therapeutics from a “sell” rating to a “neutral” rating and upped their price objective for the company from $213.00 to $215.00 in a research note on Monday, February 12th. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. SVB Leerink started coverage on shares of United Therapeutics in a research note on Monday, February 5th. They set an “outperform” rating and a $330.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $294.25.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Blue Trust Inc. raised its stake in shares of United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 46 shares during the period. Formidable Asset Management LLC raised its stake in shares of United Therapeutics by 1.5% in the 3rd quarter. Formidable Asset Management LLC now owns 3,636 shares of the biotechnology company’s stock valued at $821,000 after acquiring an additional 53 shares during the period. Alaska Permanent Fund Corp grew its holdings in United Therapeutics by 1.7% during the 3rd quarter. Alaska Permanent Fund Corp now owns 3,330 shares of the biotechnology company’s stock valued at $752,000 after purchasing an additional 57 shares in the last quarter. MBM Wealth Consultants LLC increased its stake in United Therapeutics by 2.7% during the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock worth $515,000 after buying an additional 59 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in United Therapeutics by 1.6% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock worth $856,000 after buying an additional 61 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.